Strength in numbers

The war on HIV has taught some important lessons, in particular the need to evaluate clinical results in a larger context. Trials that yield unimpressive results for single drugs may nevertheless indicate good candidates for use in combination therapies. A recent example comes from a relatively new class of antiviral agent, non-nucleoside reverse transcriptase inhibitors (NNRTIs).


Read the full 561 word article

How to gain access

Continue reading with a
two-week free trial.